Syringic acid is a dietary plant compound. Animal work links high oral doses to better glucose handling, less liver fat, and lower blood pressure. Purified oral use has not been tested in controlled trials; human data are small topical skin studies. Food from olives and grapes is the documented exposure. High-dose purified use has low-certainty benefits and mainly unknown risks. (Full Review)

Protocol

Food-level intake

about 1.8–3.4 mg/day

Olives, grapes, wine, dates, pumpkin, walnuts, and chard; only human exposure with population-diet data

Experimental isolated oral range

roughly 140–560 mg/day

Body-size scaling from 25–100 mg/kg rodent doses for a 70 kg adult; no human oral dose-finding study

Time of day

With a meal

Usual timing; fat can raise absorption. Isolated free acid is a split-with-meals candidate

Time to effect

Glucose handling

2–16 weeks

Rodent metabolic papers; no human oral time-to-effect exists

Fat mass and liver fat

12–16 weeks

Rodent high-fat-diet and ovariectomy models

Blood pressure

2–16 weeks

Rodent nitric-oxide–blocked models; no human oral time-to-effect exists

Benefits

Low: Improved glucose handling; lower fat mass, triglycerides, and hepatic fat; lower blood pressure in nitric-oxide–blocked hypertension; protection against experimental cardiac injury; reduced inflammatory skin-lesion burden; less experimental liver injury

Speculative: Neuroprotection in injury and toxin models; higher bone density after ovarian hormone loss; less experimental colitis via the gut microbiota; anticancer activity in cells and chemical carcinogenesis models; longer life in a worm model

Contraindications

Pregnancy and lactation

Children

Known hypersensitivity to syringic acid or related hydroxybenzoic acids

Uncontrolled hypotension or recurrent hypoglycemia, if isolated high-dose oral use is contemplated

Handling bulk research powder without gloves and eye protection (GHS skin, eye, and airway irritation)

Key Interactions

Antihypertensive medications (lisinopril, losartan, amlodipine)

Glucose-lowering medications (metformin, insulin, empagliflozin)

Other polyphenols (resveratrol, ferulic acid, quercetin)

High-fat meals and lipid vehicles

Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs; ibuprofen, naproxen)

Risk & Side Effects

Low: High-dose rodent hematologic and intake shifts; additive blood-pressure lowering; additive glucose lowering

Speculative: Powder irritation; high-concentration ROS cytotoxicity

Monitoring

Marker	Target	Why
Fasting glucose	75–90 mg/dL	Detects additive glucose lowering
HbA1c	4.8–5.3%	Three-month glucose exposure
Fasting insulin	3–8 µIU/mL	Insulin-sensitivity context
Triglycerides	<80 mg/dL	Lipid and liver-fat signal in mice
ALT	Track vs own baseline; functional often <20–25 U/L	Liver is the main exposure organ
AST	Track vs own baseline; functional often <25 U/L	Paired liver-cell enzyme
hs-CRP	<0.7 mg/L	Downstream inflammatory tone
Sitting/standing BP	~110–120 / 70–80 mmHg if tolerated	Additive pressure lowering

Cadence: Weekly home blood pressure and fasting glucose for the first 4 weeks of isolated use, then laboratories at 4 weeks and every 3–6 months if use continues. Food-only changes at the next routine panel.

Qualitative Assessment

Energy and post-meal alertness (possible glucose-handling proxy)
Orthostatic lightheadedness (possible excess pressure drop)
Skin comfort if a topical preparation is used
Gut comfort (stool frequency, cramping) if isolated oral doses are high

Syringic Acid for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment